Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc. is a genomic medicine company dedicated to translating groundbreaking science into medicines that aim to transform the lives of patients suffering from severe diseases for which current treatments offer only symptom management. Headquartered in Richmond, California, the company focuses on developing cell and gene therapies, particularly for neurological diseases.

The company leverages proprietary technologies, including its zinc finger protein (ZFP) platform for precise genome editing, gene therapy, gene regulation, and cell therapy applications. Sangamo also utilizes the SIFTER AAV capsid engineering platform and the Modular Integrase (MINT) genome editing platform. Its pipeline includes investigational treatments for conditions such as Fabry disease (ST-920), chronic neuropathic pain, prion disease, hemophilia A, and lysosomal storage diseases. Sangamo has established collaborations with major pharmaceutical companies, including Pfizer, Biogen, Sanofi, Takeda, Alexion, Astellas, Lilly, and Genentech, to advance its therapeutic programs.

Led by CEO Sandy Macrae, Sangamo Therapeutics has recently faced significant corporate developments. On June 23, 2026, the company filed for Chapter 11 bankruptcy protection and entered into asset sale agreements with Lilly and Astellas as part of a strategy to maximize stakeholder value. This followed its transition from the NASDAQ to the OTCQB Venture Market under the ticker symbol SGMOQ in May 2026, due to non-compliance with Nasdaq's minimum bid price requirements. Despite these challenges, Sangamo continues to progress a rolling Biologics License Application (BLA) submission for ST-920, its gene therapy candidate for Fabry disease.